Tango Therapeutics (TNGX) Assets Average (2020 - 2026)
Tango Therapeutics (TNGX) posted quarterly Assets Average of $417.2 million for Q1 2026, up 41.25% year-over-year from $295.4 million in Q1 2025, and up 37.06% quarter-over-quarter from $304.4 million in Q4 2025.
Tango Therapeutics (TNGX) Assets Average (2020 - 2026) Analysis & Trends
Tango Therapeutics' Assets Average history runs 7 years deep, the most recent figure standing at $417.2 million for Q1 2026.
- In Q1 2026, Assets Average rose 41.25% year-over-year to $417.2 million; the TTM figure through Mar 2026 stood at $417.2 million (up 41.25% YoY), while the FY2025 annual figure was $357.6 million, down 0.54% from the prior year.
- Assets Average for Q1 2026 stood at $417.2 million, up from $304.4 million in the prior quarter.
- The five-year high for Assets Average was $485.8 million in Q1 2022, with the low at $224.0 million in Q3 2025.
- The 5-year median for Assets Average is $403.8 million (2023), against an average of $381.2 million.
- The sharpest annual moves came in 2022 and 2025: Assets Average soared 173.94% in 2022, then slumped 38.95% in 2025.
- Tango Therapeutics' Assets Average stood at $450.3 million in 2022, then declined by 7.76% to $415.4 million in 2023, then slipped by 19.48% to $334.5 million in 2024, then retreated by 8.98% to $304.4 million in 2025, then soared by 37.06% to $417.2 million in 2026.
- Business Quant data shows TNGX's Assets Average at $417.2 million in Q1 2026, $304.4 million in Q4 2025, and $224.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | 754.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 754.84 Mn |
| Mar 31, 2026 | 417.24 Mn |
| Dec 31, 2025 | 304.41 Mn |
| Sep 30, 2025 | 224.01 Mn |
| Jun 30, 2025 | 256.10 Mn |
| Mar 31, 2025 | 295.40 Mn |
| Dec 31, 2024 | 334.45 Mn |
| Sep 30, 2024 | 366.93 Mn |
| Jun 30, 2024 | 393.84 Mn |
| Mar 31, 2024 | 404.39 Mn |
| Dec 31, 2023 | 415.38 Mn |
| Sep 30, 2023 | 403.76 Mn |
| Jun 30, 2023 | 391.55 Mn |
| Mar 31, 2023 | 420.12 Mn |
| Dec 31, 2022 | 450.31 Mn |
| Sep 30, 2022 | 456.28 Mn |
| Jun 30, 2022 | 459.96 Mn |
| Mar 31, 2022 | 485.84 Mn |
| Dec 31, 2021 | 515.15 Mn |
| Sep 30, 2021 | 348.84 Mn |